MXPA03009355A - Procedimientos para la preparacion del virus de la enfermedad de marek utilizando lineas celulares continuas de aves. - Google Patents

Procedimientos para la preparacion del virus de la enfermedad de marek utilizando lineas celulares continuas de aves.

Info

Publication number
MXPA03009355A
MXPA03009355A MXPA03009355A MXPA03009355A MXPA03009355A MX PA03009355 A MXPA03009355 A MX PA03009355A MX PA03009355 A MXPA03009355 A MX PA03009355A MX PA03009355 A MXPA03009355 A MX PA03009355A MX PA03009355 A MXPA03009355 A MX PA03009355A
Authority
MX
Mexico
Prior art keywords
distortion
amplifier
signal
amplified
output
Prior art date
Application number
MXPA03009355A
Other languages
English (en)
Inventor
Sing Rong
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MXPA03009355A publication Critical patent/MXPA03009355A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/255—Marek's disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16351—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16361—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Amplifiers (AREA)

Abstract

La presente invencion se refiere a lineas celulares de ave que son una base eficaz para el crecimiento e infeccion productiva del virus de la enfermedad de Marek (MDV) a altas concentraciones; la presente invencion se refiere tambien a lineas celulares de aves que se han producido por ingenieria genetica como bases para el crecimiento e infeccion productiva de virus de la enfermedad de Marek recombinante a altas concentraciones; la presente invencion se refiere a un procedimiento para la preparacion de virus de la enfermedad de Marek en cantidades adecuadas con fines de preparacion de vacunas.
MXPA03009355A 1998-12-09 2003-10-10 Procedimientos para la preparacion del virus de la enfermedad de marek utilizando lineas celulares continuas de aves. MXPA03009355A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11162798P 1998-12-09 1998-12-09

Publications (1)

Publication Number Publication Date
MXPA03009355A true MXPA03009355A (es) 2004-03-02

Family

ID=22339565

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03009355A MXPA03009355A (es) 1998-12-09 2003-10-10 Procedimientos para la preparacion del virus de la enfermedad de marek utilizando lineas celulares continuas de aves.

Country Status (13)

Country Link
US (2) US6410297B1 (es)
EP (1) EP1038952A3 (es)
JP (2) JP3284118B2 (es)
CN (1) CN1191355C (es)
AR (1) AR019786A1 (es)
AU (2) AU767470B2 (es)
BR (1) BR9905779A (es)
CA (1) CA2289951A1 (es)
HK (1) HK1027595A1 (es)
MX (1) MXPA03009355A (es)
NZ (1) NZ501129A (es)
TW (1) TWI224139B (es)
ZA (1) ZA997114B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1178111A1 (en) 2000-08-03 2002-02-06 Lohmann Animal Health GmbH & Co. KG Vaccination against host cell-associated herpesviruses
EP1471937B1 (en) * 2002-02-06 2009-07-22 Lohmann Animal Health GmbH & Co. KG A continuous cell line for the production of vaccines
CA2652731A1 (en) * 2008-02-07 2009-08-07 Mark Iv Industries Corp. Real-time location systems and methods
WO2013057236A1 (en) * 2011-10-21 2013-04-25 Intervet International B.V. Recombinant non-pathogenic marek's disease virus constructs encoding infectious laryngotracheitis virus and newcastle disease virus antigens
CN103157107A (zh) * 2011-12-14 2013-06-19 普莱柯生物工程股份有限公司 用连续传代细胞系生产鸡马立克氏病疫苗及方法
EP3050572A1 (en) * 2015-01-29 2016-08-03 Ceva Sante Animale Recombinant MDV1 and the uses thereof
US10476549B1 (en) * 2018-05-04 2019-11-12 Futurewei Technologies, Inc. Transmitter linearity built-in-self-test

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8401120A (nl) * 1984-04-09 1985-11-01 Centraal Diergeneeskundig Inst Viruspreparaat, waarmee gevaccineerd kan worden tegen de ziekte van marek.
US5928648A (en) 1985-09-06 1999-07-27 Syntro Corporation Recombinant herpesvirus of turkeys and uses thereof
JP2779447B2 (ja) * 1988-03-20 1998-07-23 財団法人阪大微生物病研究会 弱毒マレック病ウイルス・ベクターを用いる組換え遺伝子作成法、及び該ウイルスの組換え体
ES2070997T3 (es) 1989-12-04 1995-06-16 Akzo Nobel Nv Virus de herpes recombinante de pavos y vacunas vector vivas derivadas de los mismos.
FR2719056B1 (fr) * 1994-04-20 1996-09-06 Rhone Merieux Herpesvirus transformés pour exprimer gD in vitro.
JPH11500014A (ja) * 1995-02-21 1999-01-06 キャンタブ ファーマシューティカルズ リサーチ リミティド ウイルス調製物、ベクター、免疫原、及びワクチン
EP0748867A1 (en) * 1995-06-12 1996-12-18 Duphar International Research B.V Marek's disease vaccine
US5827738A (en) * 1995-10-27 1998-10-27 Board Of Trustees Operating Michigan State University Sustainable chick cell line infected with Marek's disease virus
US6475770B1 (en) * 1997-06-10 2002-11-05 Pfizer, Inc. Processes for preparation of Marek's Disease using continuous mammalian cell lines

Also Published As

Publication number Publication date
BR9905779A (pt) 2001-02-06
ZA997114B (en) 2001-05-15
AR019786A1 (es) 2002-03-13
HK1027595A1 (en) 2001-01-19
AU2004200571A1 (en) 2004-03-11
JP2001206854A (ja) 2001-07-31
EP1038952A3 (en) 2001-06-27
CN1191355C (zh) 2005-03-02
CA2289951A1 (en) 2000-06-09
JP3284118B2 (ja) 2002-05-20
CN1256310A (zh) 2000-06-14
JP2000166582A (ja) 2000-06-20
AU767470B2 (en) 2003-11-13
AU5958399A (en) 2000-06-15
US6410297B1 (en) 2002-06-25
NZ501129A (en) 2001-08-31
TWI224139B (en) 2004-11-21
EP1038952A2 (en) 2000-09-27
US20020132337A1 (en) 2002-09-19
JP3626409B2 (ja) 2005-03-09

Similar Documents

Publication Publication Date Title
EP1014564A3 (en) Feedforward amplifier
AU2001263241A1 (en) High linearity multicarrier rf amplifier
MY122083A (en) Echo canceler for non-linear circuits
EP0948130A3 (en) Article comprising a power amplifier with feed forward linearizer using a tracking algorithm
EP0840285A3 (en) Active noise conditioning system
CA2145918A1 (en) Feedforward Amplifier with Reduced Distortion in Wide Band
CA2388512A1 (en) Improved predistortion compensation for a power amplifier
EP0772310A3 (en) OFDM active deflectors
MY108184A (en) Feed forward amplifier network with frequency swept pilot tone.
EP1162732A3 (en) A linear amplifier arrangement
WO2004075397A3 (en) Enhanced efficiency feed forward power amplifier utilizing reduced cancellation bandwidth and small error amplifier
AU2001266472A1 (en) Transmitter including a composit amplifier
EP1253708A3 (en) Distortion canceling circuit
EP1257052A3 (en) Demodulator
WO1999012264A3 (en) Sigma-delta modulator with improved gain accuracy
WO2007106337A3 (en) Enhanced efficiency feed forward power amplifier with delay mismatched error cancellation loop
MXPA03009355A (es) Procedimientos para la preparacion del virus de la enfermedad de marek utilizando lineas celulares continuas de aves.
EP1296448A3 (en) Amplifier with multiple inputs
AU1519201A (en) Linearisation of an amplifier
EP1276227A3 (en) Feedforward amplifier
EP1067696A3 (en) Distortion compensation method and wireless communication apparatus
EP1100147A3 (en) Power amplifier system for an antenna system
SE9704284D0 (sv) En förstärkare och ett förfarande i förstärkaren
GB8611965D0 (en) Amplifying circuit arrangement
EP1309081A3 (en) Feed forward amplification apparatus for compensating non-linear distortion

Legal Events

Date Code Title Description
FA Abandonment or withdrawal